Exploration of [2 + 2 + 2] Cyclotrimerisation Methodology to Prepare Tetrahydroisoquinoline-based Compounds with Potential Aldo-keto Reductase 1C3 Target Affinity

Overview

Journal Medchemcomm

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2019 Nov 2

PMID 31673310

Authors

Ana R N Santos

Helen M Sheldrake

Ali I M Ibrahim

Chhanda Charan Danta

Davide Bonanni

Martina Daga

Simonetta Oliaro-Bosso

Donatella Boschi

Marco L Lolli

Klaus Pors

Affiliations

Soon will be listed here.

Abstract

Tetrahydroisoquinoline (THIQ) is a key structural component in many biologically active molecules including natural products and synthetic pharmaceuticals. Here, we report on the use of transition-metal mediated [2 + 2 + 2] cyclotrimerisation of alkynes to generate tricyclic THIQs with potential to selectively inhibit AKR1C3.

References

Pingaew R, Mandi P, Nantasenamat C, Prachayasittikul S, Ruchirawat S, Prachayasittikul V . Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity. Eur J Med Chem. 2014; 81:192-203. DOI: 10.1016/j.ejmech.2014.05.019. View

Pippione A, Giraudo A, Bonanni D, Carnovale I, Marini E, Cena C . Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach. Eur J Med Chem. 2017; 139:936-946. DOI: 10.1016/j.ejmech.2017.08.046. View

Lovering A, Ride J, Bunce C, Desmond J, Cummings S, White S . Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res. 2004; 64(5):1802-10. DOI: 10.1158/0008-5472.can-03-2847. View

Pors K, Goldberg F, Leamon C, Rigby A, Snyder S, Falconer R . The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrow. Drug Discov Today. 2009; 14(21-22):1045-50. DOI: 10.1016/j.drudis.2009.07.004. View

Lolli M, Carnovale I, Pippione A, Wahlgren W, Bonanni D, Marini E . Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3. ACS Med Chem Lett. 2019; 10(4):437-443. PMC: 6466513. DOI: 10.1021/acsmedchemlett.8b00484. View

Patil N, Wu H, Yamamoto Y . A route to 2-substituted tetrahydroquinolines via palladium-catalyzed intramolecular hydroamination of anilino-alkynes. J Org Chem. 2007; 72(17):6577-9. DOI: 10.1021/jo0708137. View

Verma K, Zang T, Penning T, Trippier P . Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. J Med Chem. 2019; 62(7):3590-3616. PMC: 6528660. DOI: 10.1021/acs.jmedchem.9b00090. View

Pippione A, Carnovale I, Bonanni D, Sini M, Goyal P, Marini E . Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid. Eur J Med Chem. 2018; 150:930-945. DOI: 10.1016/j.ejmech.2018.03.040. View

Adeniji A, Chen M, Penning T . AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol. 2013; 137:136-49. PMC: 3805777. DOI: 10.1016/j.jsbmb.2013.05.012. View

10.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

11.

Byrns M, Jin Y, Penning T . Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J Steroid Biochem Mol Biol. 2010; 125(1-2):95-104. PMC: 3047600. DOI: 10.1016/j.jsbmb.2010.11.004. View

12.

Scott J, Williams R . Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem Rev. 2002; 102(5):1669-730. DOI: 10.1021/cr010212u. View

13.

Zhou Y, Kim Y, Mohammed K, Jones D, Muhammad I, Dunbar D . Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells. J Nat Prod. 2005; 68(6):947-50. PMC: 2907142. DOI: 10.1021/np050029m. View

14.

Tian Y, Zhao L, Wang Y, Zhang H, Xu D, Zhao X . Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells. Asian J Androl. 2015; 18(4):607-12. PMC: 4955188. DOI: 10.4103/1008-682X.169997. View

15.

Lolli M, Narramore S, Fishwick C, Pors K . Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century. Drug Discov Today. 2015; 20(8):1018-26. DOI: 10.1016/j.drudis.2015.04.010. View

16.

Kahsai A, Zhu S, Wardrop D, Lane W, Fenteany G . Quinocarmycin analog DX-52-1 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44. Chem Biol. 2006; 13(9):973-83. DOI: 10.1016/j.chembiol.2006.07.011. View